Open Label Extension for 43USSA1812

NCT ID: NCT04595331

Last Updated: 2025-06-26

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

111 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-12

Study Completion Date

2022-07-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate long-term safety and effectiveness data of Sculptra Aesthetic beyond the Month 12 duration of the pivotal study 43USSA1812 (NCT04124692) to help characterize the long-term safety and effectiveness profile of the more dilute suspension.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cheek Wrinkle

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Subjects originally randomized to Control Group at baseline in the pivotal 43USSA1812 study will be offered treatment with Sculptra Aesthetic in the extension study. Subjects originally randomized to Treatment Group at baseline in the pivotal 43USSA1812 study will be continued to be followed up during the extension study without further treatment.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A: Sculptra Aesthetic

Subjects in this group will be treated with Sculptra aesthetic. Subjects will be followed for up to 12 months for safety and effectiveness data collection

Group Type EXPERIMENTAL

Sculptra Aethestic reconsituted with 8ml Sterile Water for Injection

Intervention Type DEVICE

Sculptra Aesthetic 8ml and Lidocaine treatment of cheek wrinkles

Group B: No Treatment

Subjects in this group will be followed for up to 12 months with no additional treatment for long-term safety and effectiveness data collection.

Group Type EXPERIMENTAL

Sculptra Aethestic reconsituted with 8ml Sterile Water for Injection

Intervention Type DEVICE

Sculptra Aesthetic 8ml and Lidocaine treatment of cheek wrinkles

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sculptra Aethestic reconsituted with 8ml Sterile Water for Injection

Sculptra Aesthetic 8ml and Lidocaine treatment of cheek wrinkles

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject completed Month 12 of study 43USSA1812
2. Subjects willing to comply with the requirements of the extension of the study and providing a signed written informed consent.
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Galderma R&D

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Galderma Research Site

Scottsdale, Arizona, United States

Site Status

Galderma Research Site

Encino, California, United States

Site Status

Galderma Research Site

Redondo Beach, California, United States

Site Status

Galderma Research site

San Diego, California, United States

Site Status

Galderma Research Site

Washington D.C., District of Columbia, United States

Site Status

Galderma Research Site

Coral Gables, Florida, United States

Site Status

Galderma Research Site

Alpharetta, Georgia, United States

Site Status

Galderma Research Site

New Orleans, Louisiana, United States

Site Status

Galderma Research Site

Rockville, Maryland, United States

Site Status

Galderma Research Site

New York, New York, United States

Site Status

Galderma Research Site

New York, New York, United States

Site Status

Galderma Research Site

Dallas, Texas, United States

Site Status

Galderma Research Site

Spring, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

43USSA1812ext

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.